Codexis (CDXS) vs Protara Therapeutics (TARA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Codexis (CDXS) has outperformed Protara Therapeutics (TARA) over the past year, losing 44.9% versus a loss of 47.7%. Over five years, TARA leads with a -61.3% price change compared with -95.0% for CDXS. Protara Therapeutics is the larger company by market cap ($156.6 million vs $148.9 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CDXS | TARA |
|---|---|---|
| Share price | $1.36 | $2.65 |
| Market cap | $148.93M | $156.60M |
| 1-day change | -3.55% | +2.32% |
| YTD return | -13.50% | -50.28% |
| 1-year return | -44.92% | -47.73% |
| 5-year return | -95.02% | -61.26% |
| EPS (TTM) | $-0.32 | $-1.36 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.98 | $7.82 |
| 52-week low | $0.96 | $2.51 |
| Distance from 52-week high | -54.36% | -66.11% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +351.47% | +870.19% |
| Average volume | 1.12M | 804.10K |
| Shares outstanding | 109.51M | 59.10M |
| Employees | 146 | 46 |
| Sector | Industrials | Health Care |
| Industry | Major Chemicals | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- The two companies sit in different sectors: Codexis in Industrials and Protara Therapeutics in Health Care.
About Codexis
CDXS stock →Codexis, Inc. provides technology solutions for therapeutics manufacturing, leveraging its proprietary CodeEvolver technology platform to discover, develop, enhance, and commercialize novel enzymes in the United States, Canada, Latin America, Europe, the Middle East, Africa, Australia, New Zealand, Southeast Asia, and China.
Industrials · Major Chemicals · 146 employees
About Protara Therapeutics
TARA stock →Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 46 employees
CDXS vs TARA FAQ
Which is bigger, Codexis or Protara Therapeutics?
Protara Therapeutics (TARA) is larger, with a market capitalization of $156.60M compared with $148.93M for Codexis (CDXS).
Which stock has performed better over the past year, CDXS or TARA?
CDXS returned -44.92% over the past 12 months, compared with -47.73% for TARA (price return, excluding dividends). Past performance does not predict future results.
Are Codexis and Protara Therapeutics in the same industry?
No. Codexis is in the Industrials sector, while Protara Therapeutics is in Health Care.